Activin Receptor Type 1 - Pipeline Review, H2 2019
Activin Receptor Type 1 - Pipeline Review, H2 2019
SUMMARY
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Activin Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Activin A receptor type I (ACVR1) is a protein is encoded by the ACVR1 gene. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. It acts as a receptor for activin. It is involved for left-right pattern formation during embryogenesis. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Oncology, Cardiovascular, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders and Toxicology which include indications Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Alport Syndrome, Anemia of Chronic Disease, Chemotherapy Induced Anemia, Chronic Kidney Disease (Chronic Renal Failure), Kidney Fibrosis, Knee Osteoarthritis, Myelofibrosis, Myocardial Fibrosis, Obesity, Pediatric Diffuse Intrinsic Pontine Glioma, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Solid Tumor, Thrombocythemia Myelofibrosis and Type 2 Diabetes.
Furthermore, this report also reviews key players involved in Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Activin Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Activin A receptor type I (ACVR1) is a protein is encoded by the ACVR1 gene. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. It acts as a receptor for activin. It is involved for left-right pattern formation during embryogenesis. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Oncology, Cardiovascular, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders and Toxicology which include indications Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Alport Syndrome, Anemia of Chronic Disease, Chemotherapy Induced Anemia, Chronic Kidney Disease (Chronic Renal Failure), Kidney Fibrosis, Knee Osteoarthritis, Myelofibrosis, Myocardial Fibrosis, Obesity, Pediatric Diffuse Intrinsic Pontine Glioma, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Solid Tumor, Thrombocythemia Myelofibrosis and Type 2 Diabetes.
Furthermore, this report also reviews key players involved in Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30)
- The report reviews Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics and enlists all their major and minor projects
- The report assesses Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Overview
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Companies Involved in Therapeutics Development
BioCryst Pharmaceuticals Inc
Clementia Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Ember Therapeutics Inc (Inactive)
Keros Therapeutics Inc
La Jolla Pharmaceutical Company
M4K Pharma Inc
Oncodesign SA
Sierra Oncology Inc
Tolero Pharmaceuticals Inc
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Drug Profiles
Antibody to Antagonize ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-9250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-9499 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-782 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMP-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipyridamole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KER-047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
momelotinib dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Activin Receptor-Like Kinase 2 for fibrodysplasia ossificans progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ACVR1 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Dormant Products
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Discontinued Products
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Product Development Milestones
Featured News & Press Releases
Dec 07, 2019: Sierra Oncology reports decreased transfusion requirements for patients treated with Momelotinib directly compared to Ruxolitinib at ASH annual meeting
Dec 02, 2019: Sierra Oncology announces investor event to discuss Momelotinib data being reported at ASH
Nov 21, 2019: Sierra Oncology initiates study of momelotinib in myelofibrosis
Nov 06, 2019: Sierra Oncology to report new analyses supporting Momelotinib's anemia benefits at ASH 2019
Nov 04, 2019: BioCryst launches trial to treat fibrodysplasia ossificans progressiva
Oct 24, 2019: Oncodesign: publication of an article presenting promising results for the treatment of stone man syndrome (FOP)
Jun 27, 2019: Sierra Oncology launches campaign exploring non-dilutive strategic options to support development of its DDR Assets
Jun 07, 2019: FDA grants fast-track designation to bone marrow cancer drug
Jun 04, 2019: Sierra announces FDA regulatory clarity for Momelotinib & design of the MOMENTUM phase 3 clinical trial
May 28, 2019: Sierra Oncology to Present Momelotinib Overview at the Jefferies Global Healthcare Conference in New York
Mar 27, 2019: Blueprint Medicines provides update on clinical progress of BLU-782
Feb 27, 2019: Tolero Pharmaceuticals to present new data evaluating investigational agent TP-0184 at AACR Annual Meeting 2019
Dec 03, 2018: Sierra Oncology reports robust transfusion independence rates in transfusion dependent myelofibrosis patients treated with momelotinib
Nov 27, 2018: Sierra Oncology to host analyst call highlighting clinical data on Momelotinib's anemia benefit
Nov 01, 2018: Sierra Oncology to report clinical data at ASH 2018 from translational biology study of Momelotinib in transfusion dependent patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Overview
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Companies Involved in Therapeutics Development
BioCryst Pharmaceuticals Inc
Clementia Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Ember Therapeutics Inc (Inactive)
Keros Therapeutics Inc
La Jolla Pharmaceutical Company
M4K Pharma Inc
Oncodesign SA
Sierra Oncology Inc
Tolero Pharmaceuticals Inc
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Drug Profiles
Antibody to Antagonize ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-9250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-9499 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-782 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMP-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipyridamole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KER-047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
momelotinib dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Activin Receptor-Like Kinase 2 for fibrodysplasia ossificans progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ACVR1 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Dormant Products
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Discontinued Products
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Product Development Milestones
Featured News & Press Releases
Dec 07, 2019: Sierra Oncology reports decreased transfusion requirements for patients treated with Momelotinib directly compared to Ruxolitinib at ASH annual meeting
Dec 02, 2019: Sierra Oncology announces investor event to discuss Momelotinib data being reported at ASH
Nov 21, 2019: Sierra Oncology initiates study of momelotinib in myelofibrosis
Nov 06, 2019: Sierra Oncology to report new analyses supporting Momelotinib's anemia benefits at ASH 2019
Nov 04, 2019: BioCryst launches trial to treat fibrodysplasia ossificans progressiva
Oct 24, 2019: Oncodesign: publication of an article presenting promising results for the treatment of stone man syndrome (FOP)
Jun 27, 2019: Sierra Oncology launches campaign exploring non-dilutive strategic options to support development of its DDR Assets
Jun 07, 2019: FDA grants fast-track designation to bone marrow cancer drug
Jun 04, 2019: Sierra announces FDA regulatory clarity for Momelotinib & design of the MOMENTUM phase 3 clinical trial
May 28, 2019: Sierra Oncology to Present Momelotinib Overview at the Jefferies Global Healthcare Conference in New York
Mar 27, 2019: Blueprint Medicines provides update on clinical progress of BLU-782
Feb 27, 2019: Tolero Pharmaceuticals to present new data evaluating investigational agent TP-0184 at AACR Annual Meeting 2019
Dec 03, 2018: Sierra Oncology reports robust transfusion independence rates in transfusion dependent myelofibrosis patients treated with momelotinib
Nov 27, 2018: Sierra Oncology to host analyst call highlighting clinical data on Momelotinib's anemia benefit
Nov 01, 2018: Sierra Oncology to report clinical data at ASH 2018 from translational biology study of Momelotinib in transfusion dependent patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by BioCryst Pharmaceuticals Inc, H2 2019
Pipeline by Clementia Pharmaceuticals Inc, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Ember Therapeutics Inc (Inactive), H2 2019
Pipeline by Keros Therapeutics Inc, H2 2019
Pipeline by La Jolla Pharmaceutical Company, H2 2019
Pipeline by M4K Pharma Inc, H2 2019
Pipeline by Oncodesign SA, H2 2019
Pipeline by Sierra Oncology Inc, H2 2019
Pipeline by Tolero Pharmaceuticals Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by BioCryst Pharmaceuticals Inc, H2 2019
Pipeline by Clementia Pharmaceuticals Inc, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Ember Therapeutics Inc (Inactive), H2 2019
Pipeline by Keros Therapeutics Inc, H2 2019
Pipeline by La Jolla Pharmaceutical Company, H2 2019
Pipeline by M4K Pharma Inc, H2 2019
Pipeline by Oncodesign SA, H2 2019
Pipeline by Sierra Oncology Inc, H2 2019
Pipeline by Tolero Pharmaceuticals Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
BioCryst Pharmaceuticals Inc
Clementia Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Ember Therapeutics Inc (Inactive)
Keros Therapeutics Inc
La Jolla Pharmaceutical Company
M4K Pharma Inc
Oncodesign SA
Sierra Oncology Inc
Tolero Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
BioCryst Pharmaceuticals Inc
Clementia Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Ember Therapeutics Inc (Inactive)
Keros Therapeutics Inc
La Jolla Pharmaceutical Company
M4K Pharma Inc
Oncodesign SA
Sierra Oncology Inc
Tolero Pharmaceuticals Inc
